25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PHM (Pharma Mar S.A.) Stock Analysis
Buy, Hold or Sell?

Let's analyze Pharma Mar S.A. together

I guess you are interested in Pharma Mar S.A.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Pharma Mar S.A.’s Financial Insights
  • 📈 Technical Analysis (TA) – Pharma Mar S.A.’s Price Targets

I'm going to help you getting a better view of Pharma Mar S.A.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Pharma Mar S.A.

I send you an email if I find something interesting about Pharma Mar S.A..

1. Quick Overview

1.1. Quick analysis of Pharma Mar S.A. (30 sec.)










1.2. What can you expect buying and holding a share of Pharma Mar S.A.? (30 sec.)

How much money do you get?

How much money do you get?
€0.76
When do you have the money?
1 year
How often do you get paid?
45.0%

What is your share worth?

Current worth
€11.41
Expected worth in 1 year
€11.82
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
€1.06
Return On Investment
1.3%

For what price can you sell your share?

Current Price per Share
€81.35
Expected price per share
€71.00 - €92.75
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Pharma Mar S.A. (5 min.)




Live pricePrice per Share (EOD)
€81.35
Intrinsic Value Per Share
€-116.84 - €5.37
Total Value Per Share
€-105.43 - €16.78

2.2. Growth of Pharma Mar S.A. (5 min.)




Is Pharma Mar S.A. growing?

Current yearPrevious yearGrowGrow %
How rich?$232.2m$236m-$9.7m-4.3%

How much money is Pharma Mar S.A. making?

Current yearPrevious yearGrowGrow %
Making money$5.8m$595.7k$5.2m89.8%
Net Profit Margin10.0%1.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Pharma Mar S.A. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#228 / 884

Most Revenue
#144 / 884

Most Profit
#96 / 884

Most Efficient
#123 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Pharma Mar S.A.?

Welcome investor! Pharma Mar S.A.'s management wants to use your money to grow the business. In return you get a share of Pharma Mar S.A..

First you should know what it really means to hold a share of Pharma Mar S.A.. And how you can make/lose money.

Speculation

The Price per Share of Pharma Mar S.A. is €81.35. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharma Mar S.A..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharma Mar S.A., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €11.41. Based on the TTM, the Book Value Change Per Share is €0.10 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.16 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharma Mar S.A..

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.27-0.3%0.330.4%0.030.0%0.260.3%0.750.9%0.390.5%
Usd Book Value Change Per Share-0.47-0.6%0.120.1%-0.29-0.4%0.020.0%0.420.5%0.230.3%
Usd Dividend Per Share0.000.0%0.190.2%0.190.2%0.190.2%0.180.2%0.130.2%
Usd Total Gains Per Share-0.47-0.6%0.310.4%-0.10-0.1%0.210.3%0.610.7%0.360.4%
Usd Price Per Share95.51-71.31-38.93-59.31-68.60-35.81-
Price to Earnings Ratio-88.95-24.87-37.57-42.03-33.61-15.85-
Price-to-Total Gains Ratio-203.44-134.20-149.05-123.85-87.98-40.16-
Price to Book Ratio7.11-5.44-2.94-4.41-6.61-3.75-
Price-to-Total Gains Ratio-203.44-134.20-149.05-123.85-87.98-40.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share95.68387
Number of shares10
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.190.18
Usd Book Value Change Per Share0.120.42
Usd Total Gains Per Share0.310.61
Gains per Quarter (10 shares)3.106.06
Gains per Year (10 shares)12.4124.26
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
185271714
2151014153438
3231426225162
4301938296886
53824503685110
646296244102134
753347451119158
861388658136182
969439865153206
10764811073170230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%18.02.00.090.0%23.017.00.057.5%29.036.00.044.6%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%13.07.00.065.0%19.021.00.047.5%27.038.00.041.5%
Dividend per Share1.00.03.025.0%3.00.09.025.0%8.00.012.040.0%18.00.022.045.0%22.00.043.033.8%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%14.06.00.070.0%20.020.00.050.0%31.034.00.047.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Pharma Mar S.A. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3990.102-492%-0.244-39%0.017-2402%0.361-210%0.195-305%
Book Value Per Share--11.41310.959+4%11.285+1%11.385+0%9.847+16%5.969+91%
Current Ratio--2.9692.802+6%2.849+4%2.845+4%2.926+1%2.083+43%
Debt To Asset Ratio--0.4080.423-4%0.420-3%0.428-5%0.502-19%0.663-38%
Debt To Equity Ratio--0.6890.736-6%0.724-5%0.750-8%1.125-39%28.534-98%
Dividend Per Share---0.162-100%0.163-100%0.163-100%0.154-100%0.112-100%
Enterprise Value--1409816992.8001065397447.510+32%613433550.560+130%911363175.735+55%1053780320.545+34%492312963.407+186%
Eps---0.2280.281-181%0.027-938%0.224-202%0.637-136%0.334-168%
Ev To Ebitda Ratio---320.705-24.090-92%11.268-2946%-8.083-97%1.336-24097%324.290-199%
Ev To Sales Ratio--9.0706.113+48%3.805+138%5.306+71%5.613+62%2.556+255%
Free Cash Flow Per Share---0.392-0.261-33%-0.485+24%-0.242-38%0.278-241%0.288-236%
Free Cash Flow To Equity Per Share---0.786-0.340-57%-0.929+18%-0.508-35%-0.099-87%0.067-1272%
Gross Profit Margin--2.561-0.341+113%-0.496+119%-0.838+133%-0.274+111%1.269+102%
Intrinsic Value_10Y_max--5.372----------
Intrinsic Value_10Y_min---116.840----------
Intrinsic Value_1Y_max--1.066----------
Intrinsic Value_1Y_min---2.809----------
Intrinsic Value_3Y_max--2.800----------
Intrinsic Value_3Y_min---16.198----------
Intrinsic Value_5Y_max--4.050----------
Intrinsic Value_5Y_min---37.987----------
Market Cap1403686115.0000%1404994992.8001062666197.510+32%588204550.560+139%896120175.735+57%1045237220.545+34%546279338.407+157%
Net Profit Margin---0.1020.100-202%0.010-1078%0.092-211%0.208-149%0.071-243%
Operating Margin---0.0790.073-208%-0.039-51%0.037-314%0.188-142%0.056-243%
Operating Ratio--1.0790.969+11%1.042+4%0.963+12%0.811+33%0.943+14%
Pb Ratio7.128+0%7.1155.444+31%2.940+142%4.407+61%6.611+8%3.755+89%
Pe Ratio-89.1110%-88.94624.868-458%37.570-337%42.026-312%33.607-365%15.851-661%
Price Per Share81.350+0%81.20060.630+34%33.100+145%50.425+61%58.325+39%30.445+167%
Price To Free Cash Flow Ratio-51.8410%-51.746-342.810+562%5.040-1127%-126.682+145%-145.278+181%-74.524+44%
Price To Total Gains Ratio-203.8130%-203.438134.202-252%149.051-236%123.854-264%87.976-331%40.161-607%
Quick Ratio--3.2483.2640%3.484-7%3.210+1%3.397-4%2.256+44%
Return On Assets---0.0120.014-183%0.001-1000%0.011-203%0.033-136%0.014-186%
Return On Equity---0.0200.024-182%0.002-1106%0.020-199%0.081-125%-2.065+10228%
Total Gains Per Share---0.3990.264-251%-0.081-80%0.180-322%0.516-177%0.307-230%
Usd Book Value--232266566.400226237071.150+3%236007176.450-2%238309882.000-3%207069598.330+12%126221844.650+84%
Usd Book Value Change Per Share---0.4690.120-492%-0.287-39%0.020-2402%0.425-210%0.229-305%
Usd Book Value Per Share--13.42412.889+4%13.273+1%13.391+0%11.582+16%7.021+91%
Usd Dividend Per Share---0.190-100%0.191-100%0.191-100%0.181-100%0.132-100%
Usd Enterprise Value--1658226746.9311253120477.761+32%721520542.169+130%1071945367.300+55%1239456413.024+34%579058507.559+186%
Usd Eps---0.2680.330-181%0.032-938%0.264-202%0.749-136%0.393-168%
Usd Free Cash Flow---7984045.600-5377292.350-33%-10227059.000+28%-5048936.517-37%5974507.900-234%6240329.100-228%
Usd Free Cash Flow Per Share---0.461-0.307-33%-0.571+24%-0.284-38%0.326-241%0.339-236%
Usd Free Cash Flow To Equity Per Share---0.924-0.400-57%-1.093+18%-0.597-35%-0.117-87%0.079-1272%
Usd Market Cap1651015608.4630%1652555110.5311249907981.511+32%691846192.369+139%1054016550.700+57%1229408018.804+34%642533757.834+157%
Usd Price Per Share95.684+0%95.50771.313+34%38.932+145%59.310+61%68.601+39%35.809+167%
Usd Profit---4644813.8005844537.800-179%595745.300-880%4968856.900-193%13656740.580-134%6912997.880-167%
Usd Revenue--45704779.60051678405.350-12%47677267.000-4%50480837.717-9%56960307.880-20%53932033.955-15%
Usd Total Gains Per Share---0.4690.310-251%-0.096-80%0.212-322%0.606-177%0.361-230%
 EOD+3 -5MRQTTM+14 -26YOY+19 -213Y+14 -265Y+14 -2610Y+16 -24

3.3 Fundamental Score

Let's check the fundamental score of Pharma Mar S.A. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-89.111
Price to Book Ratio (EOD)Between0-17.128
Net Profit Margin (MRQ)Greater than0-0.102
Operating Margin (MRQ)Greater than0-0.079
Quick Ratio (MRQ)Greater than13.248
Current Ratio (MRQ)Greater than12.969
Debt to Asset Ratio (MRQ)Less than10.408
Debt to Equity Ratio (MRQ)Less than10.689
Return on Equity (MRQ)Greater than0.15-0.020
Return on Assets (MRQ)Greater than0.05-0.012
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Pharma Mar S.A. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.200
Ma 20Greater thanMa 5081.825
Ma 50Greater thanMa 10081.071
Ma 100Greater thanMa 20084.412
OpenGreater thanClose80.100
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Pharma Mar S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Fundamental data was last updated by Penke on 2025-06-12 23:33:10.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Pharma Mar S.A. earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Pharma Mar S.A. to the Biotechnology industry mean.
  • A Net Profit Margin of -10.2% means that €-0.10 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharma Mar S.A.:

  • The MRQ is -10.2%. The company is making a huge loss. -2
  • The TTM is 10.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-10.2%TTM10.0%-20.1%
TTM10.0%YOY1.0%+8.9%
TTM10.0%5Y20.8%-10.8%
5Y20.8%10Y7.1%+13.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.2%-92.7%+82.5%
TTM10.0%-141.4%+151.4%
YOY1.0%-186.1%+187.1%
3Y9.2%-248.3%+257.5%
5Y20.8%-338.6%+359.4%
10Y7.1%-488.9%+496.0%
4.3.1.2. Return on Assets

Shows how efficient Pharma Mar S.A. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharma Mar S.A. to the Biotechnology industry mean.
  • -1.2% Return on Assets means that Pharma Mar S.A. generated €-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharma Mar S.A.:

  • The MRQ is -1.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-1.2%TTM1.4%-2.6%
TTM1.4%YOY0.1%+1.3%
TTM1.4%5Y3.3%-1.8%
5Y3.3%10Y1.4%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.2%-11.5%+10.3%
TTM1.4%-11.6%+13.0%
YOY0.1%-11.4%+11.5%
3Y1.1%-11.8%+12.9%
5Y3.3%-12.1%+15.4%
10Y1.4%-13.8%+15.2%
4.3.1.3. Return on Equity

Shows how efficient Pharma Mar S.A. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharma Mar S.A. to the Biotechnology industry mean.
  • -2.0% Return on Equity means Pharma Mar S.A. generated €-0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharma Mar S.A.:

  • The MRQ is -2.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 2.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-2.0%TTM2.4%-4.4%
TTM2.4%YOY0.2%+2.2%
TTM2.4%5Y8.1%-5.6%
5Y8.1%10Y-206.5%+214.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.0%-13.6%+11.6%
TTM2.4%-14.9%+17.3%
YOY0.2%-14.4%+14.6%
3Y2.0%-17.0%+19.0%
5Y8.1%-17.9%+26.0%
10Y-206.5%-20.1%-186.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Pharma Mar S.A..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Pharma Mar S.A. is operating .

  • Measures how much profit Pharma Mar S.A. makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharma Mar S.A. to the Biotechnology industry mean.
  • An Operating Margin of -7.9% means the company generated €-0.08  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharma Mar S.A.:

  • The MRQ is -7.9%. The company is operating very inefficient. -2
  • The TTM is 7.3%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ-7.9%TTM7.3%-15.3%
TTM7.3%YOY-3.9%+11.3%
TTM7.3%5Y18.8%-11.4%
5Y18.8%10Y5.6%+13.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-229.2%+221.3%
TTM7.3%-250.3%+257.6%
YOY-3.9%-205.1%+201.2%
3Y3.7%-220.2%+223.9%
5Y18.8%-342.6%+361.4%
10Y5.6%-475.5%+481.1%
4.3.2.2. Operating Ratio

Measures how efficient Pharma Mar S.A. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.08 means that the operating costs are €1.08 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Pharma Mar S.A.:

  • The MRQ is 1.079. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.969. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ1.079TTM0.969+0.111
TTM0.969YOY1.042-0.073
TTM0.9695Y0.811+0.158
5Y0.81110Y0.943-0.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0792.110-1.031
TTM0.9692.704-1.735
YOY1.0423.063-2.021
3Y0.9633.576-2.613
5Y0.8114.713-3.902
10Y0.9436.512-5.569
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Pharma Mar S.A..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Pharma Mar S.A. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.97 means the company has €2.97 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharma Mar S.A.:

  • The MRQ is 2.969. The company is able to pay all its short-term debts. +1
  • The TTM is 2.802. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.969TTM2.802+0.167
TTM2.802YOY2.849-0.047
TTM2.8025Y2.926-0.124
5Y2.92610Y2.083+0.843
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9693.661-0.692
TTM2.8023.786-0.984
YOY2.8494.121-1.272
3Y2.8454.680-1.835
5Y2.9265.765-2.839
10Y2.0836.150-4.067
4.4.3.2. Quick Ratio

Measures if Pharma Mar S.A. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharma Mar S.A. to the Biotechnology industry mean.
  • A Quick Ratio of 3.25 means the company can pay off €3.25 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharma Mar S.A.:

  • The MRQ is 3.248. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.264. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.248TTM3.264-0.016
TTM3.264YOY3.484-0.220
TTM3.2645Y3.397-0.133
5Y3.39710Y2.256+1.141
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2482.826+0.422
TTM3.2643.128+0.136
YOY3.4843.782-0.298
3Y3.2104.304-1.094
5Y3.3975.703-2.306
10Y2.2566.454-4.198
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Pharma Mar S.A..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Pharma Mar S.A. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharma Mar S.A. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Pharma Mar S.A. assets are financed with 40.8% credit (debt) and the remaining percentage (100% - 40.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharma Mar S.A.:

  • The MRQ is 0.408. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.423. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.408TTM0.423-0.015
TTM0.423YOY0.420+0.003
TTM0.4235Y0.502-0.079
5Y0.50210Y0.663-0.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4080.324+0.084
TTM0.4230.347+0.076
YOY0.4200.327+0.093
3Y0.4280.339+0.089
5Y0.5020.349+0.153
10Y0.6630.382+0.281
4.5.4.2. Debt to Equity Ratio

Measures if Pharma Mar S.A. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharma Mar S.A. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 68.9% means that company has €0.69 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharma Mar S.A.:

  • The MRQ is 0.689. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.736. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.689TTM0.736-0.047
TTM0.736YOY0.724+0.012
TTM0.7365Y1.125-0.389
5Y1.12510Y28.534-27.409
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6890.383+0.306
TTM0.7360.436+0.300
YOY0.7240.410+0.314
3Y0.7500.446+0.304
5Y1.1250.460+0.665
10Y28.5340.509+28.025
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Pharma Mar S.A. generates.

  • Above 15 is considered overpriced but always compare Pharma Mar S.A. to the Biotechnology industry mean.
  • A PE ratio of -88.95 means the investor is paying €-88.95 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharma Mar S.A.:

  • The EOD is -89.111. Based on the earnings, the company is expensive. -2
  • The MRQ is -88.946. Based on the earnings, the company is expensive. -2
  • The TTM is 24.868. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-89.111MRQ-88.946-0.164
MRQ-88.946TTM24.868-113.814
TTM24.868YOY37.570-12.703
TTM24.8685Y33.607-8.739
5Y33.60710Y15.851+17.756
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-89.111-2.197-86.914
MRQ-88.946-2.027-86.919
TTM24.868-2.527+27.395
YOY37.570-3.733+41.303
3Y42.026-3.717+45.743
5Y33.607-6.036+39.643
10Y15.851-6.649+22.500
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharma Mar S.A.:

  • The EOD is -51.841. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -51.746. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -342.810. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-51.841MRQ-51.746-0.096
MRQ-51.746TTM-342.810+291.065
TTM-342.810YOY5.040-347.851
TTM-342.8105Y-145.278-197.532
5Y-145.27810Y-74.524-70.754
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-51.841-3.007-48.834
MRQ-51.746-2.704-49.042
TTM-342.810-3.627-339.183
YOY5.040-4.334+9.374
3Y-126.682-5.070-121.612
5Y-145.278-8.532-136.746
10Y-74.524-9.305-65.219
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Pharma Mar S.A. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.11 means the investor is paying €7.11 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharma Mar S.A.:

  • The EOD is 7.128. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.115. Based on the equity, the company is overpriced. -1
  • The TTM is 5.444. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD7.128MRQ7.115+0.013
MRQ7.115TTM5.444+1.670
TTM5.444YOY2.940+2.504
TTM5.4445Y6.611-1.166
5Y6.61110Y3.755+2.856
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.1281.921+5.207
MRQ7.1151.843+5.272
TTM5.4442.113+3.331
YOY2.9402.467+0.473
3Y4.4072.541+1.866
5Y6.6113.666+2.945
10Y3.7554.311-0.556
4.6.2. Total Gains per Share

2.4. Latest News of Pharma Mar S.A.

Does Pharma Mar S.A. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Pharma Mar S.A. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-17
11:35
Global Growth Companies With High Insider Ownership June 2025Read
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Net Income  2,300-1,0631,2372,6673,90414,78018,684-22,633-3,949
Net Income from Continuing Operations  2,300-1,0631,2372,6673,90414,78018,684-22,633-3,949



6.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets333,496
Total Liabilities136,024
Total Stockholder Equity197,472
 As reported
Total Liabilities 136,024
Total Stockholder Equity+ 197,472
Total Assets = 333,496

Assets

Total Assets333,496
Total Current Assets236,009
Long-term Assets97,487
Total Current Assets
Cash And Cash Equivalents 60,292
Short-term Investments 80,554
Net Receivables 36,771
Inventory 50,525
Other Current Assets 7,867
Total Current Assets  (as reported)236,009
Total Current Assets  (calculated)236,009
+/-0
Long-term Assets
Property Plant Equipment 58,259
Long-term Assets  (as reported)97,487
Long-term Assets  (calculated)58,259
+/- 39,228

Liabilities & Shareholders' Equity

Total Current Liabilities79,491
Long-term Liabilities56,533
Total Stockholder Equity197,472
Total Current Liabilities
Short-term Debt 11,704
Short Long Term Debt 9,916
Accounts payable 42,002
Other Current Liabilities 25,785
Total Current Liabilities  (as reported)79,491
Total Current Liabilities  (calculated)89,407
+/- 9,916
Long-term Liabilities
Long term Debt 38,592
Capital Lease Obligations 3,432
Long-term Liabilities Other 197
Long-term Liabilities  (as reported)56,533
Long-term Liabilities  (calculated)42,221
+/- 14,312
Total Stockholder Equity
Common Stock10,933
Retained Earnings 164,847
Other Stockholders Equity 21,692
Total Stockholder Equity (as reported)197,472
Total Stockholder Equity (calculated)197,472
+/-0
Other
Capital Stock10,933
Cash and Short Term Investments 140,846
Common Stock Shares Outstanding 17,303
Liabilities and Stockholders Equity 333,496
Net Debt -8,352
Net Invested Capital 245,980
Net Working Capital 156,518
Property Plant and Equipment Gross 58,259
Short Long Term Debt Total 51,940



6.3. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-31
> Total Assets 
0
0
0
207,540
206,152
231,050
228,539
211,314
215,986
242,725
238,550
230,823
220,888
227,721
221,028
217,816
212,203
230,490
218,473
199,830
216,484
207,367
201,867
189,370
205,202
220,042
213,559
201,389
205,770
223,109
245,691
211,939
217,991
220,531
209,525
221,137
216,641
222,195
202,710
187,720
185,649
190,618
174,850
157,676
166,103
129,738
112,537
124,705
275,611
352,227
329,731
330,259
345,102
342,542
347,692
368,386
378,028
390,772
379,098
393,259
373,717
358,690
349,412
341,223
333,898
317,102
333,129
349,644
333,496
333,496349,644333,129317,102333,898341,223349,412358,690373,717393,259379,098390,772378,028368,386347,692342,542345,102330,259329,731352,227275,611124,705112,537129,738166,103157,676174,850190,618185,649187,720202,710222,195216,641221,137209,525220,531217,991211,939245,691223,109205,770201,389213,559220,042205,202189,370201,867207,367216,484199,830218,473230,490212,203217,816221,028227,721220,888230,823238,550242,725215,986211,314228,539231,050206,152207,540000
   > Total Current Assets 
0
0
0
124,925
124,934
149,540
147,732
126,386
131,402
157,917
153,753
143,407
133,428
139,527
133,636
129,531
124,195
142,453
130,792
106,431
122,688
113,966
107,960
95,895
111,435
122,430
116,761
101,916
104,992
120,742
140,333
112,135
118,599
122,056
109,847
120,992
113,904
123,647
104,299
93,176
92,188
97,930
88,272
75,110
39,881
66,874
50,751
49,976
202,583
259,470
237,859
245,651
261,420
276,683
280,941
295,231
289,149
274,689
265,939
275,183
257,475
267,839
260,973
252,602
241,357
224,113
238,020
250,248
236,009
236,009250,248238,020224,113241,357252,602260,973267,839257,475275,183265,939274,689289,149295,231280,941276,683261,420245,651237,859259,470202,58349,97650,75166,87439,88175,11088,27297,93092,18893,176104,299123,647113,904120,992109,847122,056118,599112,135140,333120,742104,992101,916116,761122,430111,43595,895107,960113,966122,688106,431130,792142,453124,195129,531133,636139,527133,428143,407153,753157,917131,402126,386147,732149,540124,934124,925000
       Cash And Cash Equivalents 
0
0
0
37,807
29,196
33,686
45,977
37,246
34,017
20,470
22,896
40,595
29,007
24,831
18,825
30,381
19,653
25,125
26,424
18,336
30,432
13,630
14,572
22,458
19,626
22,723
23,898
16,551
14,951
22,943
39,533
7,629
6,550
8,633
10,595
14,290
11,926
19,628
13,670
24,088
15,886
14,677
26,164
22,745
10,385
39,327
23,409
17,638
153,992
208,892
93,222
96,210
106,432
129,587
132,167
113,348
152,255
142,723
129,433
149,813
119,711
76,070
69,975
60,024
35,709
19,319
34,800
63,239
60,292
60,29263,23934,80019,31935,70960,02469,97576,070119,711149,813129,433142,723152,255113,348132,167129,587106,43296,21093,222208,892153,99217,63823,40939,32710,38522,74526,16414,67715,88624,08813,67019,62811,92614,29010,5958,6336,5507,62939,53322,94314,95116,55123,89822,72319,62622,45814,57213,63030,43218,33626,42425,12519,65330,38118,82524,83129,00740,59522,89620,47034,01737,24645,97733,68629,19637,807000
       Short-term Investments 
0
0
0
0
24,565
28,692
26,254
0
26,133
43,205
38,991
25,985
20,437
16,633
23,512
18,944
17,402
24,614
18,074
16,092
8,141
6,062
6,470
6,377
13,648
12,707
12,518
18,960
15,778
7,840
9,641
37,996
36,965
30,803
21,797
18,077
28,188
21,471
17,872
7,671
7,674
4,270
4,265
4,131
3,393
3,394
3,597
3,257
19,612
19,214
104,023
99,306
103,627
87,145
88,947
88,532
69,333
53,973
56,917
32,607
63,416
108,826
104,378
102,538
124,010
115,828
109,593
91,288
80,554
80,55491,288109,593115,828124,010102,538104,378108,82663,41632,60756,91753,97369,33388,53288,94787,145103,62799,306104,02319,21419,6123,2573,5973,3943,3934,1314,2654,2707,6747,67117,87221,47128,18818,07721,79730,80336,96537,9969,6417,84015,77818,96012,51812,70713,6486,3776,4706,0628,14116,09218,07424,61417,40218,94423,51216,63320,43725,98538,99143,20526,133026,25428,69224,5650000
       Net Receivables 
0
0
0
55,851
39,325
0
46,503
61,207
41,644
64,742
64,587
42,829
50,350
65,580
60,581
52,151
55,662
61,865
59,080
48,952
53,584
65,445
62,193
44,832
49,945
58,592
54,669
0
42,657
60,635
62,683
39,513
46,684
55,832
51,544
61,859
43,894
50,845
44,259
31,388
36,510
48,249
32,844
23,549
12,504
11,678
11,682
13,242
16,793
17,738
27,452
26,710
26,850
27,608
26,036
56,347
30,801
32,115
29,154
29,324
24,447
25,936
30,182
47,834
26,945
30,159
33,698
34,677
36,771
36,77134,67733,69830,15926,94547,83430,18225,93624,44729,32429,15432,11530,80156,34726,03627,60826,85026,71027,45217,73816,79313,24211,68211,67812,50423,54932,84448,24936,51031,38844,25950,84543,89461,85951,54455,83246,68439,51362,68360,63542,657054,66958,59249,94544,83262,19365,44553,58448,95259,08061,86555,66252,15160,58165,58050,35042,82964,58764,74241,64461,20746,503039,32555,851000
       Other Current Assets 
0
0
0
60,678
42,095
87,162
49,417
39,051
44,275
67,037
67,248
47,630
53,659
67,991
63,625
54,897
58,392
65,511
60,986
48,952
56,726
67,162
63,364
44,832
52,365
61,898
56,142
42,001
45,626
62,780
64,863
4,007
3,444
2,007
2,912
4,608
4,624
7,041
5,354
6,125
5,271
4,833
5,126
4,069
63,868
3,386
3,522
8,649
3,461
4,050
4,588
14,148
15,789
21,599
23,252
31,907
21,027
27,288
28,928
35,693
17,283
21,448
21,546
23,197
11,215
11,560
12,168
10,158
7,867
7,86710,15812,16811,56011,21523,19721,54621,44817,28335,69328,92827,28821,02731,90723,25221,59915,78914,1484,5884,0503,4618,6493,5223,38663,8684,0695,1264,8335,2716,1255,3547,0414,6244,6082,9122,0073,4444,00764,86362,78045,62642,00156,14261,89852,36544,83263,36467,16256,72648,95260,98665,51158,39254,89763,62567,99153,65947,63067,24867,03744,27539,05149,41787,16242,09560,678000
   > Long-term Assets 
0
0
0
82,615
81,218
81,510
80,807
84,928
84,584
84,808
84,797
87,416
87,460
88,194
87,392
88,285
88,008
88,037
87,681
92,948
93,345
93,045
93,844
93,471
93,767
97,612
96,798
99,473
100,778
102,367
105,358
99,804
99,392
98,475
99,678
100,145
102,737
98,548
98,411
94,544
93,461
92,688
86,578
82,566
65,987
62,864
61,786
74,729
73,028
92,757
91,872
84,608
83,681
65,859
66,751
73,155
88,879
116,083
113,159
118,076
116,242
90,851
88,439
88,621
92,541
92,989
95,109
99,396
97,487
97,48799,39695,10992,98992,54188,62188,43990,851116,242118,076113,159116,08388,87973,15566,75165,85983,68184,60891,87292,75773,02874,72961,78662,86465,98782,56686,57892,68893,46194,54498,41198,548102,737100,14599,67898,47599,39299,804105,358102,367100,77899,47396,79897,61293,76793,47193,84493,04593,34592,94887,68188,03788,00888,28587,39288,19487,46087,41684,79784,80884,58484,92880,80781,51081,21882,615000
       Property Plant Equipment 
0
0
0
39,903
39,773
39,343
38,743
39,062
38,243
37,786
37,373
36,570
35,753
35,307
34,498
33,862
32,825
32,348
31,490
29,794
29,290
29,040
28,800
27,959
27,857
28,288
28,686
29,218
30,367
30,678
31,116
30,624
30,946
30,954
31,473
31,141
30,929
30,863
30,978
31,207
31,111
31,333
27,059
26,637
25,899
26,620
26,473
25,797
24,985
25,118
24,990
25,499
26,753
27,180
28,745
30,605
30,639
30,077
27,688
34,715
34,148
39,186
43,006
47,607
53,740
54,738
57,671
59,080
58,259
58,25959,08057,67154,73853,74047,60743,00639,18634,14834,71527,68830,07730,63930,60528,74527,18026,75325,49924,99025,11824,98525,79726,47326,62025,89926,63727,05931,33331,11131,20730,97830,86330,92931,14131,47330,95430,94630,62431,11630,67830,36729,21828,68628,28827,85727,95928,80029,04029,29029,79431,49032,34832,82533,86234,49835,30735,75336,57037,37337,78638,24339,06238,74339,34339,77339,903000
       Goodwill 
0
0
0
2,548
0
0
0
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000002,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5480002,548000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,138
1,022
1,021
1,024
977
947
963
885
884
872
868
822
1,029
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,0298228688728848859639479771,0241,0211,0221,13800000000000000000000000000000000000
       Intangible Assets 
0
0
0
11,769
0
0
0
12,528
12,763
13,232
13,775
14,448
14,955
15,920
16,736
17,325
18,063
18,186
18,552
19,744
20,437
20,840
21,412
22,590
23,019
23,535
24,735
26,288
26,420
27,584
26,128
26,829
26,106
25,382
25,756
24,900
24,148
23,659
23,143
20,212
19,301
18,382
17,443
16,658
5,691
4,763
3,949
6,074
5,287
4,785
0
3,860
0
0
0
3,233
0
0
0
2,589
2,403
2,220
0
1,935
0
1,427
1,238
1,000
0
01,0001,2381,42701,93502,2202,4032,5890003,2330003,86004,7855,2876,0743,9494,7635,69116,65817,44318,38219,30120,21223,14323,65924,14824,90025,75625,38226,10626,82926,12827,58426,42026,28824,73523,53523,01922,59021,41220,84020,43719,74418,55218,18618,06317,32516,73615,92014,95514,44813,77513,23212,76312,52800011,769000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
451
451
356
63
4
0
0
0
0
0
0
0
0
0
0
0
56,188
44,090
43,004
40,718
51,192
39,554
39,462
38,643
42,555
60,235
30,613
30,542
47,243
41,727
41,802
41,791
37,890
1
34,261
33,736
34,409
27,443
28,298
28,103
30,529
30,807
31,164
0
0
0
0
0
0
0
000000031,16430,80730,52928,10328,29827,44334,40933,73634,261137,89041,79141,80241,72747,24330,54230,61360,23542,55538,64339,46239,55451,19240,71843,00444,09056,188000000000004633564514510000000000000000000
> Total Liabilities 
0
0
0
158,196
160,737
182,055
182,087
170,178
175,507
203,631
201,625
195,963
189,824
198,272
198,244
183,314
183,339
185,503
177,532
161,104
161,945
154,489
149,213
139,935
139,350
154,948
147,781
141,320
139,641
150,581
168,779
138,903
152,521
161,887
153,414
172,642
170,545
179,003
167,480
164,736
164,003
164,484
146,610
140,203
158,606
133,518
121,746
117,249
198,229
248,729
231,581
227,537
217,577
207,688
204,487
190,468
176,227
183,836
166,594
170,302
156,786
148,388
143,217
147,785
141,224
135,721
150,958
141,285
136,024
136,024141,285150,958135,721141,224147,785143,217148,388156,786170,302166,594183,836176,227190,468204,487207,688217,577227,537231,581248,729198,229117,249121,746133,518158,606140,203146,610164,484164,003164,736167,480179,003170,545172,642153,414161,887152,521138,903168,779150,581139,641141,320147,781154,948139,350139,935149,213154,489161,945161,104177,532185,503183,339183,314198,244198,272189,824195,963201,625203,631175,507170,178182,087182,055160,737158,196000
   > Total Current Liabilities 
0
0
0
65,324
68,830
86,752
83,111
71,906
71,033
95,659
102,511
103,319
101,171
101,591
102,526
89,367
92,371
99,611
96,116
87,355
92,117
83,483
82,954
74,058
83,715
91,905
88,585
82,626
84,543
85,244
84,748
70,623
79,400
84,955
77,911
87,164
87,023
91,496
84,697
83,110
85,428
94,577
78,483
72,382
68,641
70,810
60,769
60,439
103,758
108,447
105,723
94,919
83,793
77,334
81,444
86,346
80,648
96,087
89,940
97,320
89,029
85,509
86,625
95,888
92,270
87,874
89,444
82,694
79,491
79,49182,69489,44487,87492,27095,88886,62585,50989,02997,32089,94096,08780,64886,34681,44477,33483,79394,919105,723108,447103,75860,43960,76970,81068,64172,38278,48394,57785,42883,11084,69791,49687,02387,16477,91184,95579,40070,62384,74885,24484,54382,62688,58591,90583,71574,05882,95483,48392,11787,35596,11699,61192,37189,367102,526101,591101,171103,319102,51195,65971,03371,90683,11186,75268,83065,324000
       Short-term Debt 
0
0
0
0
0
35,404
0
0
34,987
45,428
57,181
62,860
57,807
54,453
0
52,686
54,847
53,020
54,458
54,734
56,511
46,556
48,923
41,327
48,874
52,230
50,289
44,466
46,048
40,401
41,741
28,643
35,678
34,655
28,541
27,906
19,937
29,826
11,869
26,395
21,634
30,362
18,868
28,483
34,666
32,522
30,487
31,333
18,562
20,016
18,624
16,783
17,986
17,950
16,159
14,031
14,337
12,742
15,133
14,733
14,854
14,619
14,753
14,805
12,794
11,977
11,249
9,847
11,704
11,7049,84711,24911,97712,79414,80514,75314,61914,85414,73315,13312,74214,33714,03116,15917,95017,98616,78318,62420,01618,56231,33330,48732,52234,66628,48318,86830,36221,63426,39511,86929,82619,93727,90628,54134,65535,67828,64341,74140,40146,04844,46650,28952,23048,87441,32748,92346,55656,51154,73454,45853,02054,84752,686054,45357,80762,86057,18145,42834,9870035,40400000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,489
94,659
103,734
13,687
14,065
14,507
14,684
16,335
13,508
32,852
30,773
28,722
29,655
17,004
18,524
17,051
15,313
16,235
16,152
14,368
12,212
12,183
10,736
13,776
13,125
13,213
12,748
12,777
12,825
10,920
10,321
9,864
7,966
9,916
9,9167,9669,86410,32110,92012,82512,77712,74813,21313,12513,77610,73612,18312,21214,36816,15216,23515,31317,05118,52417,00429,65528,72230,77332,85213,50816,33514,68414,50714,06513,687103,73494,65995,48900000000000000000000000000000000000
       Accounts payable 
0
0
0
29,491
0
37,538
0
30,183
0
0
0
32,677
0
0
0
27,998
0
0
0
23,782
29,742
30,074
25,247
22,364
27,655
31,015
28,485
26,070
30,479
36,298
32,546
30,880
36,400
41,397
39,021
36,712
40,885
42,617
36,470
35,830
37,778
41,097
35,731
31,231
23,756
25,182
19,198
16,471
15,002
6,936
15,987
21,039
20,696
13,625
19,160
26,928
26,353
24,689
31,117
27,492
21,075
23,134
21,284
29,174
34,631
32,815
35,203
38,650
42,002
42,00238,65035,20332,81534,63129,17421,28423,13421,07527,49231,11724,68926,35326,92819,16013,62520,69621,03915,9876,93615,00216,47119,19825,18223,75631,23135,73141,09737,77835,83036,47042,61740,88536,71239,02141,39736,40030,88032,54636,29830,47926,07028,48531,01527,65522,36425,24730,07429,74223,78200027,99800032,67700030,183037,538029,491000
       Other Current Liabilities 
0
0
0
35,833
68,830
10,188
83,111
41,723
36,046
50,231
45,330
7,782
43,364
47,138
102,526
8,683
37,524
46,591
41,658
7,673
2,046
2,672
2,838
9,244
3,178
4,241
3,349
10,828
3,758
3,418
3,044
9,490
7,322
8,883
10,328
21,831
5,190
9,466
3,232
20,885
4,774
4,674
2,476
12,668
10,219
3,724
2,407
12,635
70,194
14,832
3,083
57,097
8,187
45,759
15,114
45,387
11,203
58,656
43,690
30,429
28,531
22,587
25,777
51,909
24,891
28,121
33,016
31,864
25,785
25,78531,86433,01628,12124,89151,90925,77722,58728,53130,42943,69058,65611,20345,38715,11445,7598,18757,0973,08314,83270,19412,6352,4073,72410,21912,6682,4764,6744,77420,8853,2329,4665,19021,83110,3288,8837,3229,4903,0443,4183,75810,8283,3494,2413,1789,2442,8382,6722,0467,67341,65846,59137,5248,683102,52647,13843,3647,78245,33050,23136,04641,72383,11110,18868,83035,833000
   > Long-term Liabilities 
0
0
0
92,872
91,907
95,303
98,976
98,272
104,474
107,972
99,114
92,644
88,653
96,681
95,718
93,947
90,968
85,892
81,416
73,749
69,828
71,006
66,259
65,877
55,635
63,043
59,196
58,694
55,098
65,337
84,031
68,280
73,121
76,932
75,503
85,478
83,522
87,507
82,783
81,626
78,575
69,907
68,127
67,821
89,965
62,708
60,977
56,810
94,471
140,282
125,858
132,618
133,784
130,354
123,043
104,122
95,579
87,749
76,654
72,982
67,757
62,879
56,592
51,897
48,954
47,847
61,514
58,591
56,533
56,53358,59161,51447,84748,95451,89756,59262,87967,75772,98276,65487,74995,579104,122123,043130,354133,784132,618125,858140,28294,47156,81060,97762,70889,96567,82168,12769,90778,57581,62682,78387,50783,52285,47875,50376,93273,12168,28084,03165,33755,09858,69459,19663,04355,63565,87766,25971,00669,82873,74981,41685,89290,96893,94795,71896,68188,65392,64499,114107,972104,47498,27298,97695,30391,90792,872000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,897
28,534
29,059
0
0
0
0
0
0
0
000000029,05928,53427,89700000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,895
17,600
13,600
11,105
8,019
7,910
2,665
2,567
2,899
26,056
2,091
2,137
2,028
49,399
97,457
84,209
92,736
97,382
91,073
84,698
68,820
62,219
55,871
49,369
45,085
0
0
0
0
0
0
0
0
0
00000000045,08549,36955,87162,21968,82084,69891,07397,38292,73684,20997,45749,3992,0282,1372,09126,0562,8992,5672,6657,9108,01911,10513,60017,60017,89500000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,543
0
0
0
10,976
0
0
0
5,482
0
0
0
5,151
0
0
0
2,807
0
0
0
2,105
0
0
0
1,403
0
0
0
0
0
0
0
0
0
0000000001,4030002,1050002,8070005,1510005,48200010,97600013,54300000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
49,344
45,415
48,996
46,452
41,136
40,479
39,094
36,925
34,515
33,023
33,052
27,973
39,553
35,399
48,170
44,820
42,330
58,195
56,609
56,385
53,228
69,674
68,932
69,598
63,882
69,945
76,352
80,742
76,874
69,313
62,492
59,968
52,358
49,964
47,064
39,107
26,866
25,532
30,024
32,135
21,373
11,401
129
-5,296
11,374
81,304
107,434
98,150
102,722
127,525
134,854
143,205
177,918
201,801
206,936
212,504
222,957
216,931
210,302
206,195
193,438
192,674
181,381
182,171
208,359
197,472
197,472208,359182,171181,381192,674193,438206,195210,302216,931222,957212,504206,936201,801177,918143,205134,854127,525102,72298,150107,43481,30411,374-5,29612911,40121,37332,13530,02425,53226,86639,10747,06449,96452,35859,96862,49269,31376,87480,74276,35269,94563,88269,59868,93269,67453,22856,38556,60958,19542,33044,82048,17035,39939,55327,97333,05233,02334,51536,92539,09440,47941,13646,45248,99645,41549,344000
   Common Stock
0
0
0
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
10,933
10,933
10,93310,93311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,110000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
17
0
0
19
0
0
0
19
0
0
0
15
0
15
0
0
0
000150150001900019001714000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
71,278
71,278
71,278
0
0
0
0
0
0
0
000000071,27871,27871,27800000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
296,078
296,096
63,167
306,369
311,298
312,809
312,822
313,388
313,545
314,934
314,907
314,907
316,415
317,777
317,468
316,732
316,953
317,015
317,474
317,474
317,260
316,834
316,148
315,967
314,542
313,739
323,292
323,292
66,245
65,822
65,018
66,023
65,942
66,128
67,875
66,794
66,808
66,734
67,866
68,746
69,035
69,643
69,043
69,187
69,779
67,840
59,867
36,891
49,825
48,954
48,933
46,961
45,599
49,309
53,273
50,905
55,413
48,587
51,109
46,212
40,187
37,570
25,920
22,742
29,047
21,692
21,69229,04722,74225,92037,57040,18746,21251,10948,58755,41350,90553,27349,30945,59946,96148,93348,95449,82536,89159,86767,84069,77969,18769,04369,64369,03568,74667,86666,73466,80866,79467,87566,12865,94266,02365,01865,82266,245323,292323,292313,739314,542315,967316,148316,834317,260317,474317,474317,015316,953316,732317,468317,777316,415314,907314,907314,934313,545313,388312,822312,809311,298306,36963,167296,096296,078000



6.4. Balance Sheets

Currency in EUR. All numbers in thousands.




6.5. Cash Flows

Currency in EUR. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue174,855
Cost of Revenue-8,183
Gross Profit166,672166,672
 
Operating Income (+$)
Gross Profit166,672
Operating Expense-160,204
Operating Income6,4686,468
 
Operating Expense (+$)
Research Development103,502
Selling General Administrative2,853
Selling And Marketing Expenses174
Operating Expense160,204106,529
 
Net Interest Income (+$)
Interest Income5,665
Interest Expense-2,469
Other Finance Cost-0
Net Interest Income3,196
 
Pretax Income (+$)
Operating Income6,468
Net Interest Income3,196
Other Non-Operating Income Expenses0
Income Before Tax (EBT)11,985951
EBIT - interestExpense = 11,985
11,985
28,594
Interest Expense2,469
Earnings Before Interest and Taxes (EBIT)14,45414,454
Earnings Before Interest and Taxes (EBITDA)21,225
 
After tax Income (+$)
Income Before Tax11,985
Tax Provision--14,140
Net Income From Continuing Ops26,12526,125
Net Income26,125
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses168,387
Total Other Income/Expenses Net5,517-3,196
 

Technical Analysis of Pharma Mar S.A.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharma Mar S.A.. The general trend of Pharma Mar S.A. is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharma Mar S.A.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Pharma Mar S.A. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharma Mar S.A..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 84.30 < 92.70 < 92.75.

The bearish price targets are: 78.05 > 72.50 > 71.00.

Know someone who trades $PHM? Share this with them.👇

Pharma Mar S.A. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharma Mar S.A.. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharma Mar S.A. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharma Mar S.A.. The current macd is -0.89792575.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharma Mar S.A. price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharma Mar S.A.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharma Mar S.A. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Pharma Mar S.A. Daily Moving Average Convergence/Divergence (MACD) ChartPharma Mar S.A. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharma Mar S.A.. The current adx is 13.01.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Pharma Mar S.A. shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Pharma Mar S.A. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharma Mar S.A.. The current sar is 77.30.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Pharma Mar S.A. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharma Mar S.A.. The current rsi is 49.20. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Pharma Mar S.A. Daily Relative Strength Index (RSI) ChartPharma Mar S.A. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharma Mar S.A.. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pharma Mar S.A. price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Pharma Mar S.A. Daily Stochastic Oscillator ChartPharma Mar S.A. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharma Mar S.A.. The current cci is -26.07232969.

Pharma Mar S.A. Daily Commodity Channel Index (CCI) ChartPharma Mar S.A. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharma Mar S.A.. The current cmo is 1.26753636.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Pharma Mar S.A. Daily Chande Momentum Oscillator (CMO) ChartPharma Mar S.A. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharma Mar S.A.. The current willr is -42.14285714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Pharma Mar S.A. is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Pharma Mar S.A. Daily Williams %R ChartPharma Mar S.A. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharma Mar S.A..

Pharma Mar S.A. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharma Mar S.A.. The current atr is 3.24862298.

Pharma Mar S.A. Daily Average True Range (ATR) ChartPharma Mar S.A. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharma Mar S.A.. The current obv is 2,688,488.

Pharma Mar S.A. Daily On-Balance Volume (OBV) ChartPharma Mar S.A. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharma Mar S.A.. The current mfi is 53.53.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Pharma Mar S.A. Daily Money Flow Index (MFI) ChartPharma Mar S.A. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharma Mar S.A..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Pharma Mar S.A. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharma Mar S.A. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.200
Ma 20Greater thanMa 5081.825
Ma 50Greater thanMa 10081.071
Ma 100Greater thanMa 20084.412
OpenGreater thanClose80.100
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Pharma Mar S.A. with someone you think should read this too:
  • Are you bullish or bearish on Pharma Mar S.A.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharma Mar S.A.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharma Mar S.A.

I send you an email if I find something interesting about Pharma Mar S.A..


Comments

How you think about this?

Leave a comment

Stay informed about Pharma Mar S.A..

Receive notifications about Pharma Mar S.A. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.